Design, synthesis and biological evaluation of 4-bromo-N-(3,5-dimethoxyphenyl)benzamide derivatives as novel FGFR1 inhibitors for treatment of non-small cell lung cancer

• Auteurs principaux: Zixin Xie (Auteur), Donghua Cheng (Auteur), Lu Luo (Auteur), Guoliang Shen (Auteur), Suwei Pan (Auteur), Yaqian Pan (Auteur), Bo Chen (Auteur), Xuebao Wang (Auteur), Zhiguo Liu (Auteur), Yuan Zhang (Auteur), Faqing Ye (Auteur)
• Format: Livre
• Publié: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

A series of 4-bromo-N-(3,5-dimethoxyphenyl)benzamide derivatives were designed and synthesised as novel fibroblast growth factor receptor-1 (FGFR1) inhibitors. We found that one of the most promising compounds, C9, inhibited five non-small cell lung cancer (NSCLC) cell lines with FGFR1 amplification...